The agency is discouraging doctors from performing the procedure, which uses an electronic device to grind and shred uterine tissue so it can be removed through a small incision in the abdomen. Known as laparoscopic power morcellation, the technique is widely used to treat painful fibroids, either by removing the noncancerous growths themselves or the entire uterus.
Italian law enforcement authorities are currently investing the theft. However, the situation...
GlaxoSmithKline and Genmab A/S announced that the FDA has approved a Supplemental Biologic...
Cubist Pharmaceuticals is voluntarily recalling one lot of CUBICIN® (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles, found in a single vial from this lot, produced by a contract manufacturer.
Hospira announced today that on April 2, 2014, it informed customers of a nationwide recall of seven lots of Propofol Injectable Emulsion, USP, to the user level due to a glass defect located on the interior neck of the vial, which was identified during a retain sample inspection where the glass vial contained visible embedded metal particulate. Free-floating metal particulates were also identified in vials upon further analysis
NanoSmart and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration agreement to explore the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors.
A surge of eleventh-hour enrollments has improved the outlook for President Barack Obama's health care law, with more people signing up overall and a much-needed spark of interest among young adults.
Actavis has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech.
Vince & Associates Clinical Research, a provider of comprehensive early development clinical research services for the global biopharmaceutical industry, broke ground on a new $5 million expansion of its research campus today.
U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen. Ragwitek tablets dissolve quickly under the tongue. Patients are to take one daily for a few years, starting three months before ragweed season begins in late summer.
Albany Molecular Research Inc. announced Wednesday that it will close its 12-year-old facility in Cicero on July 15. Some employees will be transferred to Albany, Cedarburg, Wis., England and India.
Mylan has launched XULANET, the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).
The Ebola virus that has killed scores of people in Guinea this year is a new strain — evidence that the disease did not spread there from outbreaks in some other African nations, scientists report.
Over the last two decades, the rates of heart attacks and strokes among diabetics fell by more than 60 percent, a new federal study shows. The research also confirms earlier reports of drastic declines in diabetes-related kidney failure and amputations.
Two former pharmaceutical and medical technology firm executives have been sentenced for their involvement in an insider trading scheme.
Jacques Servier, the founder of France's second-largest pharmaceutical group who became ensnared in a scandal over a diabetes drug widely used for weight loss, has died.
The company that owns an Evansville, Indiana printing plant says it will be shutting it down in June and eliminating nearly 60 jobs.